Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 2013

View Archived Issues

RNA interference-based nanoparticles to treat brain tumors

FDA accepts IND application for Gencaro in atrial fibrillation

Novel V1B receptor antagonists demonstrate activity in animal models of anxiety and depression

Mesoblast reports topline data from phase II study of MPCs in type 2 diabetes

FDA grants isavuconazole QIDP designation in invasive aspergillosis

MUC-1 cancer vaccine well tolerated in phase I study

Mylan acquires Agila injectables businesses from Strides Arcolab

Novartis presents novel tyrosine-protein kinase inhibitors

Edivoxetine does not meet endpoint in phase III studies in major depressive disorder

Gilead Sciences discloses novel antiviral compounds

Receptos to begin phase III part of RPC-1063 study in relapsing multiple sclerosis

Phase Ib data for MP-4-CO in patients with sickle cell anemia

Chinese group prepares new protein kinase inhibitors

FDA grants orphan drug status to KX-02 for gliomas

Actelion Pharmaceuticals synthesizes novel LXA4 receptor agonists

Ortho-McNeil-Janssen Pharmaceuticals divulges novel agents for Alzheimer's disease

Sanofi and Hanmi launch Robelito in Korea

Amgen reports new glucokinase activators for diabetes and other disorders

ALS Therapy Development Institute and Neurimmune establish research partnership

FDA approves Xiaflex for Peyronie's disease

European approval for Fluenz Tetra

DX-2930 receives FDA orphan drug designation in hereditary angioedema

FDA approves Sovaldi for chronic hepatitis C

ViiV Healthcare seeks approval for dolutegravir in Japan

Synflorix approved in Europe for immunization against pneumonia in infants and children

Ikervis MAA filed in Europe for dry eye disease

European submission of safinamide for Parkinson's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...